The TSC-mTOR signaling pathway regulates the innate inflammatory response

Weichhart T, Costantino G, Poglitsch M, Rosner M, Zeyda M, Stuhlmeier KM, Kolbe T, Stulnig TM, Hörl WH, Hengstschläger M, Müller M, Säemann MD · 2008 · Immunity · Atlas ID WEI2008

What this study shows

The TSC-mTOR pathway controls the innate inflammatory response of monocytes/macrophages.

Abstract

ShowHide

The innate inflammatory immune response must be tightly controlled to avoid damage to the host. Here, we showed that the tuberous sclerosis complex-mammalian target of rapamycin (TSC-mTOR) pathway regulated inflammatory responses after bacterial stimulation in monocytes, macrophages, and primary dendritic cells. Inhibition of mTOR by rapamycin promoted production of proinflammatory cytokines via the transcription factor NF-kappaB but blocked the release of interleukin-10 via the transcription factor STAT3.

Read the full abstract on PubMed →

At a glance

Evidence type	M Molecular — cells, biochemistry, structure Marked M because it is molecular or in-vitro work (model: Mouse/human monocytes) rather than a whole-organism health-outcome study. That is often exactly where causal biology gets established -- the code says which system the finding was shown in, and nothing about how good the work is.
Study type	5 - Mechanistic / In Vitro
Model system	Mouse/human monocytes
Journal	Immunity
Year	2008
Peer reviewed	Yes
Record last updated	2026-10-01
Source	DOI 10.1016/j.immuni.2008.08.012 · PMID 18848473

Extracted findings

These fields were extracted from the paper with AI assistance and have not been checked against the source. Read them as a pointer into the paper, not as curated claims; where they disagree with the curated summary above, the curated summary stands.

Intervention	Rapamycin (mTOR inhibition)
Target	TSC-mTOR / NF-κB
Model	Mouse/human monocytes
Effect	mTOR inhibition promotes pro-inflammatory cytokines via NF-κB – TSC-mTOR regulates the innate inflammatory response

In the Atlas

Open questions that cite this study

Cited as supporting evidence for the open question Is there a low-dose mTOR schedule whose immune effects come out favourable, compartment by compartment?.

Cite this paper

ShowHide

Weichhart, T., Costantino, G., Poglitsch, M., Rosner, M., Zeyda, M., Stuhlmeier, K. M., Kolbe, T., Stulnig, T. M., Hörl, W. H., Hengstschläger, M., Müller, M., & Säemann, M. D. (2008). The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity. https://doi.org/10.1016/j.immuni.2008.08.012

@article{WEI2008,
  author       = {Weichhart, T. and Costantino, G. and Poglitsch, M. and Rosner, M. and Zeyda, M. and Stuhlmeier, K. M. and Kolbe, T. and Stulnig, T. M. and Hörl, W. H. and Hengstschläger, M. and Müller, M. and Säemann, M. D.},
  title        = {{The TSC-mTOR signaling pathway regulates the innate inflammatory response}},
  journal      = {Immunity},
  year         = {2008},
  doi          = {10.1016/j.immuni.2008.08.012},
  note         = {PMID: 18848473},
}

Cite this Atlas record

The record is the Atlas's own work — the evidence label, the extracted findings and the links. It is cited as part of the dataset, not as the paper.

Barton, O. (2026). Oliver's mTOR Atlas (record WEI2008) [Data set]. https://mtor-atlas.org/study/WEI2008/ · Dataset DOI 10.5281/zenodo.22059963

@misc{atlas_WEI2008,
  author       = {Barton, Oliver},
  title        = {{Oliver's mTOR Atlas}, record WEI2008},
  howpublished = {Data set},
  year         = {2026},
  url          = {https://mtor-atlas.org/study/WEI2008/},
  doi          = {10.5281/zenodo.22059963}
}

Was this page useful?